Elizabeth Lim1, Matthew G Wiggans2, Golnaz Shahtahmassebi3, Somaiah Aroori4, Matthew J Bowles5, Christopher D Briggs6, David A Stell7. 1. Department of Oncology, Plymouth Hospitals NHS Trust, Plymouth, PL6 8DH, UK. Electronic address: elizabeth.lim@nhs.net. 2. Department of HPB Surgery, Plymouth Hospitals NHS Trust, Plymouth, PL6 8DH, UK; Peninsula Schools of Medicine and Dentistry, Plymouth University, Plymouth, Devon, PL6 8BU, UK. Electronic address: matthew.wiggans1@nhs.net. 3. School of Science and Technology, Nottingham Trent University, Nottingham, NG1 4BU, UK. Electronic address: golnaz.shahtahmassebi@ntu.ac.uk. 4. Department of HPB Surgery, Plymouth Hospitals NHS Trust, Plymouth, PL6 8DH, UK. Electronic address: s.aroori@nhs.net. 5. Department of HPB Surgery, Plymouth Hospitals NHS Trust, Plymouth, PL6 8DH, UK. Electronic address: matthewbowles@nhs.net. 6. Department of HPB Surgery, Plymouth Hospitals NHS Trust, Plymouth, PL6 8DH, UK. Electronic address: christopherbriggs@nhs.net. 7. Department of HPB Surgery, Plymouth Hospitals NHS Trust, Plymouth, PL6 8DH, UK; Peninsula Schools of Medicine and Dentistry, Plymouth University, Plymouth, Devon, PL6 8BU, UK. Electronic address: david.stell@nhs.net.
Abstract
BACKGROUND: A period of recovery is commonly allowed between completion of chemotherapy for colorectal liver metastases (CRLM) and resection, during which tumour progression may occur. The study-aim is to assess the growth of CRLM in this interval and association with outcome. METHOD: Data on 146 patients were analysed. Change in tumour size was assessed by comparing size determined by imaging performed on completion of chemotherapy with that determined by examination of the resected specimen, categorised by RECIST criteria. RESULTS: In the interval before surgery sixteen patients (11%) fulfilled criteria for partial response (PR), 48 (33%) had stable disease (SD) and 82 (56%) had progressive disease (PD). Among patients with PD following chemotherapy the median disease-free survival of patients who initially responded (26 months) was longer than in those who initially had stable disease (7 months) (P = 0.002). No association was noted between rate of tumour growth after completion of chemotherapy and disease-free survival. CONCLUSION: Change in tumour size after completion of chemotherapy is variable and can be rapid, especially in patients who initially respond to treatment. However, disease-free survival is determined by tumour behaviour during treatment and not by change in size after completion of chemotherapy.
BACKGROUND: A period of recovery is commonly allowed between completion of chemotherapy for colorectal liver metastases (CRLM) and resection, during which tumour progression may occur. The study-aim is to assess the growth of CRLM in this interval and association with outcome. METHOD: Data on 146 patients were analysed. Change in tumour size was assessed by comparing size determined by imaging performed on completion of chemotherapy with that determined by examination of the resected specimen, categorised by RECIST criteria. RESULTS: In the interval before surgery sixteen patients (11%) fulfilled criteria for partial response (PR), 48 (33%) had stable disease (SD) and 82 (56%) had progressive disease (PD). Among patients with PD following chemotherapy the median disease-free survival of patients who initially responded (26 months) was longer than in those who initially had stable disease (7 months) (P = 0.002). No association was noted between rate of tumour growth after completion of chemotherapy and disease-free survival. CONCLUSION: Change in tumour size after completion of chemotherapy is variable and can be rapid, especially in patients who initially respond to treatment. However, disease-free survival is determined by tumour behaviour during treatment and not by change in size after completion of chemotherapy.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: M Margaret Kemeny; Sudeshna Adak; Bruce Gray; John S Macdonald; Thomas Smith; Stuart Lipsitz; Elin R Sigurdson; Peter J O'Dwyer; Al B Benson Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 44.544
Authors: René Adam; Gerard Pascal; Denis Castaing; Daniel Azoulay; Valerie Delvart; Bernard Paule; Francis Levi; Henri Bismuth Journal: Ann Surg Date: 2004-12 Impact factor: 12.969
Authors: Birgit Gruenberger; Werner Scheithauer; Robert Punzengruber; Christoph Zielinski; Dietmar Tamandl; Thomas Gruenberger Journal: BMC Cancer Date: 2008-04-25 Impact factor: 4.430
Authors: Raphael L C Araujo; Camila G C Y Carvalho; Carlos T Maeda; Jean Michel Milani; Diogo G Bugano; Pedro Henrique Z de Moraes; Marcelo M Linhares Journal: World J Gastrointest Surg Date: 2022-09-27